Skip to main content

Table 2 Annual worsening rate estimated for this series

From: IGF-1 in autosomal dominant cerebellar ataxia - open-label trial

Patients N Annual worsening index (average ± SD) 95% confidence interval for mean
1 year − baseline SCA3 19 −1.54 ± 3.0 −2.89 −0.19
SCA7 6 −2.12 ± 2.1 −3.80 −0.44
SCA6 1 −3 −3 −3
2 nd year (extension) SCA3 6 −0.08 ± 1.11 −0.97 0.81
SCA7 4 0.63 ± 1.93 −1.26 2.52
Control SCA3 139 1.61 ± 0.12 1.59 1.63
Control SCA7 7 1.5 ± 0.9 0.79 2.21
Control SCA6 107 0.35 ± 0.34 0.29 0.41
  1. Comprehensive quantitative account of disease progression was given by Jacobi et al. [26]. N number.